Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Some of Pharma's Biggest Brands Face a New Reality
09:48am, Wednesday, 28'th Jan 2026
Big pharma just got another nudge from Washington that Medicare pricing pressure is only moving in one direction. A new batch of well-known drugs from Pfizer (P
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
06:45pm, Tuesday, 27'th Jan 2026
Pfizer (PFE) reached $26.5 at the closing of the latest trading day, reflecting a +2.4% change compared to its last close.
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
04:52pm, Tuesday, 27'th Jan 2026
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
11:01am, Tuesday, 27'th Jan 2026
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CM WEALTH ADVISORS LLC Buys 12,251 Shares of Pfizer Inc (PFE)
08:16am, Tuesday, 27'th Jan 2026
Summary CM WEALTH ADVISORS LLC initiated a new position in Pfizer Inc(PFE), purchasing 12,251 shares valued at approximately $305,050 as of its latest
Pfizer vs. Merck Stock And JNJ
07:40am, Tuesday, 27'th Jan 2026
In the last six months Pfizer's stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant upcomin
Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
06:02am, Tuesday, 27'th Jan 2026
The Great Healthcare Plan has threatened the biopharma sector with mandatory global price parity, but the market is overlooking a critical carve-out specific to Pfizer. While competitors face immediat
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag
10:06am, Monday, 26'th Jan 2026
The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk by 50% compared with current treatment.
The Best Stocks to Invest $40 in to Start the New Year Off Right
01:15pm, Saturday, 24'th Jan 2026
Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss medicine.
VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion
10:36am, Friday, 23'rd Jan 2026
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund's concentrated bet on GLP-1 manufacturers makes this
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
10:33am, Friday, 23'rd Jan 2026
Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost sav
The Top Stock to Buy With $30 for 2026
10:00am, Friday, 23'rd Jan 2026
It's a great opportunity to "buy low."
Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?
06:30am, Thursday, 22'nd Jan 2026
Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
06:45pm, Wednesday, 21'st Jan 2026
Pfizer (PFE) closed the most recent trading day at $25.9, moving +1.49% from the previous trading session.
3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer
06:26am, Wednesday, 21'st Jan 2026
Pfizer is investing in oncology and GLP-1 drugs, among other things, to keep its growth prospects bright. Western Union is planning a digital network featuring a stablecoin.
